Amneal Pharmaceuticals, Inc.
About Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $3.0B
- Net income
- $72.1M
- Total assets
- $3.7B
- Market cap
- $4.4B
- Gross margin
- 36.9%
- Operating margin
- 13.1%
- Net margin
- 4.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.0B
- Cost of revenue
- $1.9B
- Gross profit
- $1.1B
- Operating expenses
- $719.2M
- Operating income
- $394.1M
- Income tax
- $11.3M
- Net income
- $127.9M
- EPS (basic)
- $0.23
- EPS (diluted)
- $0.22
Balance sheet
- Total assets
- $3.7B
- Current assets
- $1.9B
- Total liabilities
- $3.7B
- Current liabilities
- $881.6M
- Shareholders’ equity
- -$71.3M
Cash flow
- Operating cash flow
- $340.0M
- Investing cash flow
- -$112.3M
- Financing cash flow
- -$31.5M
- Net cash flow
- $194.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $4.4B
- P/E ratio
- 62.3
- EPS (diluted)
- $0.22
- Shares outstanding
- 320.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 7, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $72.1M in FY2025.
- Revenue grew 44% from FY2021 to FY2025.
- Gross margin of 36.9%, net margin 4.2%.
- Trading 10% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 62.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Amneal Pharmaceuticals, Inc..
Write a review
News about Amneal Pharmaceuticals, Inc.
News & sentiment via Polygon.io
